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Tremendous efforts have been made to elucidate the basis of cancer biology with the aim of 20 
promoting anticancer drug development. Especially in the past twenty years, anticancer drug 21 
development has developed from conventional cytotoxic agents to target-based and immune-22 
related therapies. Consequently, more than 200 anticancer drugs are available on the market. 23 
However, anticancer drug development still suffers high attrition in the later phases of clinical 24 
development   and is considered to be a difficult and risky therapeutic category within the drug 25 
development arena. The disappointing performance of investigational anticancer candidates 26 
implies that there are some shortcomings in the translation of preclinical in vitro and in vivo 27 
models to humans, and that heterogeneity in the patient population presents a significant 28 
challenge. Here, we summarize both successful and failed experiences in anticancer 29 
development during the past 20 years and help identify why the paradigm may be suboptimal. 30 
We also offer potential strategies for improvement.  31 
 32 
Current progress of anticancer drug development 33 
Cancer, which is characterized by uncontrolled growth of cells in the body, is one of the most 34 
difficult and complex diseases to treat [1-3]. Cancer patients suffer high mortality rates, which 35 
range from 1.1% for prostate cancer to 92.3% for pancreatic cancer within five years after 36 
cancer diagnosis. Therefore, anticancer drug research and development (R&D) is a challenging 37 
and daunting activity, and the likelihood of failure is high [4]. Fewer than 5% of developed 38 
anticancer compounds reach the market [5]. Furthermore, compared to other therapeutic 39 
categories such as cardiovascular disease and arthritis, an anticancer drug has approximately 40 
one-third to one-half greater failure rate per attempt [5, 6]. Although there are a lot of 41 
difficulties and barriers in anticancer drug development, drug makers are still pursuing 42 
opportunities for anticancer drug candidates due to their high cost-benefit rate [7, 8]. For 43 
example, oncology is ranked in the top therapeutic class by global sales which amounted to 44 
78.94 billion US dollars in 2015.  45 
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Approved anticancer drugs  46 
The ultimate task for an anticancer drug is to kill the tumor cells and/or control proliferation of 47 
tumor cells to prolong patient survival and improve their quality of life. However, there are 48 
many different mechanisms by which this can be achieved.  Based on the key biochemical 49 
mechanism of anticancer action, anticancer drugs can be are categorized as: (i) nucleic acid 50 
biosynthesis blocker; (ii) the structure and function of DNA interferer; (iii) transcription interferer 51 
and RNA synthesis blocker;(iv) protein synthesis and function interferer; (v) hormone 52 
homeostasis influencer; (vi) immune system modulators. Consequently, drug makers have 53 
produced four major groups of anticancer drugs including cytotoxic drugs (alkylating agents, 54 
antimetabolites, antibiotics, plant extracts, and miscellaneous cytotoxic drugs), targeted-based 55 
agents (e.g. bevacizumab), hormones and hormones antagonists (e.g. tamoxifen), and 56 
immunomodulators (e.g. nivolumab). From the classic “Seed and soil hypothesis” that first 57 
described metastasis  [9] to the first description of “immune-based cancer therapy” [10], every 58 
milestone made in the cancer field has driven a wave of anticancer drug development [11] 59 
(Figure 1). In the past two decades, anticancer drug development has moved on from 60 
conventional non-specific cytotoxic agents which often kill proliferating normal cells as well as 61 
tumor cells [12, 13]. In the place of cytotoxic agents, there is a  focus on specific target-based 62 
cancer therapy [14] designed to hit tumor cells only, and on immune-related modulators that 63 
help the patient’s immune system to defeat tumor cells [10, 15, 16]. Furthermore, a series of 64 
regulations, initiatives, and guidance have been developed to facilitate anticancer drug 65 
development [17, 18].  66 
According to the USA National Cancer Institute drug repository, there are a total of 227 67 
approved anticancer drugs (Supplementary Table S1) to treat about 40 different types of 68 
cancers. There are multiple drug options developed for leukemia, non-Hodgkin lymphoma and 69 
breast cancers. In contrast, for some cancer types such as penile or liver cancer, there is only 70 
one drug treatment available. On average, available anticancer drugs are used to treat 3.44 71 
cancer types. For example, nivolumab (Opdivo®) is a monoclonal antibody that works as a 72 
checkpoint inhibitor by inhibiting the programmed cell death receptor 1 (PD-1), which is 73 
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overexpressed on diverse of tumor cells and is in charge of down-regulating the immune 74 
system and suppressing T cell inflammatory activity. Activated PD-1 blocks T-cell activation and 75 
aids the tumor in escaping immune detection. By blocking this PD-1 activation, nivolumab aids 76 
the immune system in attacking the tumor cells [19, 20]. Nivolumab was initially approved as a 77 
first-line anticancer drug to treat advanced melanoma in 2014. In 2015, the indication of 78 
nivolumab was expanded to squamous cell lung cancer and as a second line anticancer drug to 79 
treat renal cell carcinoma . In addition, nivolumab was also approved in 2016 to treat classical 80 
Hodgkin lymphoma (cHL) in patients who have relapsed or progressed after post-81 
transplantation brentuximab vedotin and autologous hematopoietic stem cell transplantation 82 
(auto-HSCT) . In contrast, approximately 45% of rare diseases are rare oncological diseases [21], 83 
some of which have no treatment options available on the market [22]. There is no obvious 84 
correlation between the number of drugs to treat a particular cancer and the five-year survival 85 
rate/estimated new cases  for different cancer types, which may imply that developments in 86 
treatment is mainly based on the understanding of cancer nature history and on our 87 
accumulated knowledge on pathogenesis and etiology of cancer (Figure 2). 88 
Clinical trials related cancers and other neoplasms  89 
Anticancer drug development remains a major focus of clinical trials and approximately 40% of 90 
studies in clinicaltrial.gov are relevant to the condition “Cancers and Other Neoplasms” [23]. 91 
These clinical studies are widely sponsored by drug makers, academic researchers, and federal 92 
governments. For example, the NCI has supported or sponsored a total of more than 5000 93 
cancer-related clinical trials. Among 5154 cancer-related clinical trials, about 73% (3735/5114) 94 
of clinical studies are aimed at developing treatment options for cancers. These cancer 95 
treatment-related studies are in different clinical phases with 45% in phase I, 53% in Phase II, 96 
8.6% in Phase III and only 0.6% in Phase IV. This shows that although many compounds enter 97 
the early phases (I & II), relatively few make it to Phase III or beyond. 98 
High failure rate of anticancer drugs  99 
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Ongoing efforts have uncovered cancer genetics, novel therapeutic targets, and clinical 100 
biomarkers related to survival rate, which have led to better understanding of the molecular 101 
basis of cancer. However, it seems that our ability to translate these research findings into 102 
more effective clinical cancer treatments is still remarkably limited [24, 25]. Many factors are 103 
responsible for a high attrition rate of anticancer drug development at each phase from 104 
preclinical to post-marketing of drug development.  105 
In vitro assay approaches 106 
The key challenge for preclinical in vitro and in vivo tools such as cancer-cell-lines and animal 107 
models is whether they can be used to make reliable “go/no go” decisions on which candidates 108 
to progress into the clinical phases. Concerns have been raised as to whether cancer-cell-line 109 
based assay systems can meaningfully reproduce the tumor cell behaviors in cancer patients. 110 
High-throughput screening (HTS) based In vitro assays have a lot of advantages since they can 111 
be used to conduct a rapid screen of anticancer drug candidates against different endpoints 112 
using different cancer cells [26, 27]. In the current preclinical setting of anticancer discovery, 113 
HTS in vitro assays together with combinatorial chemistry have become a standard tool to 114 
readily identify agents with clinical potential. In vitro assays have been widely applied in various 115 
cancer preclinical studies and diverse platforms such as NCI60 [28], LINCS project led by NIH 116 
[29], and anticancer drug sensitivity studies from both the Broad Institute [30] and the 117 
Wellcome Trust Sanger Institute [31].  118 
There are two major types of in vitro assay approaches for anticancer drug discovery – 119 
phenotypic screening and target-based screening. Unlike the target-based approaches based on 120 
engineered cloned genes either in cell-based or biochemical in vitro assays, phenotypic 121 
screening assays have relatively straightforward endpoints for ameliorating the cancer 122 
phenotype, which are exemplified by selectively killing cancer cells, eliminating cancer cell 123 
proliferation or decreasing the cancer cell size [32]. There is some debate on which technology 124 
contributes more to discovery of first-in-class drugs [33, 34]. Based on FDA approved drugs 125 
statistics (1999 ~ 2008), phenotypic screening took more first-in-class drugs to the market than 126 
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target-based approaches. However, another much larger scale of studies based on from 1999 to 127 
2013 drew an opposite conclusion that 78 of 113 FDA-approved first-in-class drugs are based on 128 
target-based approaches. In the anticancer drug area, target-based approaches introduced 129 
more anticancer drugs to the market [35], but both types of screening have their own values 130 
and can lead to viable drugs [37, 41]. The target-based screening approach is hypothesis-driven, 131 
in which cancer disease modeling and pathway analysis leads to a candidate protein or 132 
proteins. Compounds that perturb or interfere with the candidate protein are considered as 133 
lead compounds. The target-based approaches have had a lot of success, especially in kinase 134 
inhibitors [36]. Between 1999 and 2013, 21 of 31 oncology new molecule entities (NMEs) 135 
discovered by target-based approaches are kinase inhibitors [32]. However, the target 136 
identification and validation for anticancer drug development is of great challenge. First, 137 
validated anticancer drug targets are far more difficult to identify than we expected. Candidate 138 
anticancer targets are initially identified from different biological based HTS efforts, which is 139 
mainly hypothesis-driven. Therefore, further in-depth validation experiments are needed to 140 
establish that the proposed candidate targets have desired therapeutic effects and low risk 141 
[37]. There are fewer than 100 anticancer targets implicated in FDA-approved anticancer drugs, 142 
which is still a small proportion compared to the 20,000 human genes that encode 143 
approximately 500,000 proteins in the human genome [38, 39]. Furthermore, due to the limited 144 
and incomplete knowledge of cancer-related proteins involved in specific human malignancies, 145 
even drug candidates with high potency identified in the screening process may have little or no 146 
value. For example, colorectal tumors harboring a KRAS mutation that activate the EGFR 147 
protein signaling pathway fail to respond to EGFR inhibitors such as cetuximab (Erbitux) in 148 
mutated KRAS-related colorectal patients [40]. Also, some cancer-related tumor-suppressor 149 
genes such as RAS are not directly “druggable”, which creates another hurdle to apply target-150 
based screen approaches [41, 42]. For example, the GTPases were identified as the key 151 
enzymes to activate RAS protein. Therefore, efforts were made to inhibit GTPases to control 152 
RAS activation. However, the low molar affinity between small molecules and GTPases made 153 
inhibiting GTPases untenable. Furthermore, RAS protein function is highly associated with the 154 
inner face of the plasma membrane, further complicating controlling RAS activation, since small 155 
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molecules could not reach the RAS protein. [43]. Some advanced cell-based assay technologies 156 
including 3D in vitro assay models [44], organ-on-a-chip systems [45-47], cellular imaging [48, 157 
49], and iPSC stem cells [50] may improve the performance of target-based in vitro assay 158 
performance. For instance, the multicellular co-culture system mimics the tumor 159 
microenvironment by migrating tumor cells to adjunct microenvironment cell types such as 160 
endothelial cells and fibroblasts, thereby modeling the complex pathological features of 161 
different cancer types. This strategy has been applied for drug efficacy screening for breast 162 
cancer [51].  163 
Meanwhile, phenotypic based screening seems to be experiencing a resurgence in anticancer 164 
drug discovery [52, 53]. Phenotypic in vitro screening is considered as a semi-empirical 165 
approach that does not require knowledge of the underlying mode of action and molecular 166 
mechanisms of the compounds being evaluated. Cancer phenotypes can be observed in cell 167 
lines, and thus compounds that disrupt that phenotype may be viable drugs.  In particular, 168 
human primary cells, immortalized primary cells, and iSPCs have been widely applied to the 169 
phenotypic screening assays, which has provided a lot of success in anticancer drug discovery 170 
[34]. One example is carfilzomib, which is a selective proteasome inhibitor used to treat 171 
multiple myeloma after the patients received prior therapies such as bortezomib and 172 
lenalidomide. Proteasome inhibitors could induce apoptosis and inhibited tumor growth. 173 
Carfilzomib could reversibly bind to the chymotrypsin-like (ChT-L) active sites in the 20S 174 
proteasome, which potently control the cell growth and proliferation. The efficacy of 175 
carfilzomib was originally discovered by using a cytotoxicity screen [54]. One difficulty of the 176 
phenotypic screening approach is dosage optimation since there is no clear target for the 177 
cancer types. Other challenges include optimising chemistry against an unknown target and 178 
prediction of unwanted toxicities that may normally be elucidated from target distribution.  179 
Besides considerations regarding the biological nature of cell-based assays for anticancer drug 180 
discovery, the quality of HTS assays and how to interpret the results also play a role in better 181 
harnessing the technology. One example is the inconsistency in two large drug response data 182 
sets from the Cancer Cell line Encyclopedia (CCLE) [30] and the Genomics of Drug Sensitivity in 183 
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Cancer [31] based on cell-based HTS assays [55]. There are 15 common drugs characterized in 184 
431 cancer cell lines between the two studies, which showed a substantial divergence in drug 185 
response, although the gene expression similarity is well-established [55, 56]. There are a lot of 186 
underlying reasons contributing to the divergence. The batch effect of fetal bovine serum used 187 
in the different studies, the mathematical equation employed in curve-fitting of concentration-188 
response curves, and even the coating on plastic wells may be influential. Another potential 189 
influence on this divergence is which measure, quantitative or qualitative, should be used as 190 
the assay endpoint.  For example, the method employed to measure the metabolic activity by 191 
assessing levels of the energy transfer molecule ATP, could influence the assay’s endpoint, 192 
contributing to the observed divergence.  Due to these concerns, in vitro assay results should 193 
not be interpreted as a pure statistical measurement, but rather interpreted in the context of 194 
the generated hypotheses that each drug was tested under. [57]. Undoubtedly, the 195 
reproducibility of cell-based screening assays for anticancer drug development is of great 196 
importance [58, 59]. Considering cell-based assays are plagued with the concerns of false 197 
positive and false negatives [60], the statistical practices [61] and application domain of assays 198 
[62] need to be standardized and defined [63]. Wassermann et. al. [64] revisited the screening 199 
collection that never showed biological activity based on HTS techniques, and therefore 200 
became defined as 'dark chemical matter' (DCM). It was found that some of the false negative 201 
compounds based on HTS screening did show biological relevance under the quality control 202 
assays such as prospective reporter-gene assay gene expression experiments. Therefore, critical 203 
data quality control and wise design of  experiments is a “must” to ensure reproducible and 204 
reliable results generated from cell-based assays [65].  205 
Animal models 206 
Animal models are widely used to verify the biological relevance of the identified target for 207 
tumor response, to predict the first-in-human (FIH) dose and maximum tolerated dose (MTD), 208 
to determine the potency of anticancer drug exposure target, and to detect the qualified pre-209 
clinical prognosis, diagnosis and predictive biomarkers [66, 67]. The principle behind animal 210 
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models is that the physiological features of animals closely resemble humans in genetic, 211 
epigenetic, and environmental factors, which is open to debate. 212 
The lessons learned from animal models in anticancer drug development are mainly related to 213 
how animal models could better resemble cancer pathophysiology in humans. The challenges in 214 
extrapolation from animal studies to humans for anticancer drug development may be not only 215 
attributed to the technical and biological transferability of the animal model itself but may also 216 
involve the design, execution, and interpretation of the results from animal models [68]. Below 217 
we explore lessons learned on how to improve the animal model performance such as animal 218 
model application, and PK/PD model optimization (Figure 3).  219 
Application domain of animal models  220 
Various cancer animal models have been developed to mimic patient tumors, including human 221 
cancer cell-line based xenograft models [69], patient-derived xenografts (PDXs) [70-72], 222 
immune-competent models [73], and genetically engineered mice (GEM) [74]. The pros and 223 
cons of different kinds of animal models for anticancer drug development have been intensively 224 
discussed [66, 75-77]. The human cell-line based xenograft model was established by using the 225 
mouse as an immune-deficient host for transplanted human cancer cell-line growth. The classic 226 
example of human cancer cell-line based xenograft model is so called athymic ‘nude 227 
mouse'[69]. The transplanted human cancer cell-line model is easily tractable, controlled and 228 
experimentally convenient. However, there are also some shortcomings of this cell-line based 229 
xenograft models. First, the nude animal is immune-deficient, which does not resemble the 230 
immune environment of human tumors. Therefore, the human cell-line based xenograft models 231 
are not applicable for immune-related anticancer drug development. Second, because cell lines 232 
adapt through the clonal selection process as they grow on plastic, they do not repeat the 233 
genetic diversity seen in human tumors, nor do the cell lines reflect intratumoral heterogeneity. 234 
Additionally, the human cancer cell line is typically extracted from early-stage cancer patients.  235 
Finally, the subcutaneous location may not foster important tissue-specific stromal infiltration, 236 
which means the model is a poor fit for soft tissue sarcomas with typical tumor growth. Due to 237 
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these limitations, some reports suggest combining the different human cell line types in 238 
xenograft models may improve the performance, which has been successfully for ER+ and 239 
triple-negative breast cancers[78]. The human PDX model, which directly implants the human 240 
tumors into a mouse, has been widely applied in both academia and industry for anticancer 241 
drug development [79, 80]. The PDXs suffer similar concerns as the human cancer cell-line 242 
based xenografts regarding to lack of immune features and difficulty of tumor growth in 243 
subcutaneous regions. However, the PDXs could better replicate the mutational heterogeneity 244 
and reflect the intricacies of tumor subpopulations [81]. For example, some mutation-related 245 
cancer subtypes such as mutated ESR1 related ER+ breast cancer could be identified only in the 246 
PDX model but did not show any signal in cell-based xenograft [82]. One of the big concerns of 247 
animal models is how to mimic the immune-comprised systems of cancer patients in the mice. 248 
The immune-competent models and genetically engineered mice (GEM) successfully reproduce 249 
the immune features and tumor interaction in animals by employing different bioengineering 250 
techniques [83]. The immune-competent model is established by transplanting mouse cell line 251 
and tumor tissues to the immune-competent host with immune cells and fibroblast 252 
incorporated. The immune-competent models provide interactive immune system features and 253 
mimic tumor microenvironment, thus more closely approximating human cancers. However, 254 
the limited available cell lines for immune-component models coupled with rapid and 255 
uncontrolled cell growth limit its wide application[66]. The GEM model aims to manipulate the 256 
mouse genome to introduce the germline mutation or conditional mutations for different 257 
tumor types. Especially with the rapid development of gene editing technology, the GEM model 258 
has a promising future for cancer etiology, epigenomics and personalized cancer treatment 259 
[74]. One promising example of application of the GEM model for anticancer development is 260 
selumetinib (clinical Phase I/II/III), which is designed for multiple cancer types including triple-261 
negative breast cancer [84], non-squamous cell lung cancer [85], pancreatic cancer [86], and 262 
neurofibroma [87, 88]. One of the indications is KRAS-mutant non-small cell lung cancer 263 
(NSCLC). A co-clinical trial that combines preclinical and clinical models was employed to 264 
observe the drug response (selumetinib and docetaxel) for NSCLC in humans and in genetically 265 
engineered mice and found the selumetinib could significantly increase the efficacy of 266 
 11 
 
docetaxel, a standard chemotherapy [85]. Meanwhile, there are also many cases of failure of 267 
animal models in anticancer drug development (Table 1).  268 
No single animal model will fit all purposes. For example, the cell-based xenografts and human 269 
PDXs models are more suitable for tumor-cell-derived signal detection such as cell death and 270 
proliferation but not fit for immune-related anticancer drug discovery. GEM models and 271 
immune-component models may not be useful for intratumoral subclonal identification due to 272 
limited types of mutations and technical hurdles for monitoring internal organs[89]. A 273 
combination of animal models and cell based in vitro assays could provide more robust results. 274 
Furthermore, some novel animal models such as the 3D organoids based cell-line xenografts 275 
may also offer alternative means to further update and improve animal model 276 
performances[90].  277 
PK/PD model optimization  278 
Anticancer drugs are considered as one of the most toxic drug classes in the therapeutic 279 
spectrum [12, 91, 92]. Associated adverse drug reactions cover almost every organ system and 280 
are known to cause multiple organ toxicities, which could be explained by the nature of 281 
anticancer drugs which are intended to kill cells together with their tendency to off-target 282 
promiscuity [93]. A major difficulty is the unexpected side effects observed in the clinical phase 283 
that could not be detected in animal models, and vice versa. Dose is the key factor to balance 284 
the efficacy and safety profiles for anticancer drugs [94-96]. Due to the anticipated toxicities, 285 
Phase I clinical trials are often conducted in cancer patients under The International Council for 286 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)S9 . 287 
However, for some less toxic anticancer therapies such as targeted therapies, Phase 1 trials may 288 
be conducted in volunteers under ICH M3.  For these latter trials, one of the most important 289 
tasks for animal models is to establish the maximum recommended starting dose (MRSD) for 290 
clinical Phase I study for healthy human volunteers. The FDA has developed guidelines for the 291 
industry such as “Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial 292 
Clinical Trials for Therapeutics in Adult Healthy Volunteers”. The conventional MRSD dose 293 
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prediction strategies are based on no observed adverse effect level (NOAEL) [97] and the 294 
minimum anticipated biological effect level (MABEL) [98] approaches and have been widely 295 
applied to first-in-human (FIH) dose estimation. Currently, the FIH dose is typically calculated by 296 
using one tenth of the toxic dose in 10% of the animals (STD10), which is the dose that causes 297 
severe toxicity in 10% of rodents [99]. Typically, at least two species are required in 298 
toxicological studies: one rodent such as the rat or mouse) and one nonrodent such as the dog, 299 
minipig or monkey.  300 
PK/PD models play an increasingly important role in preclinical studies [100]. Since anticancer 301 
drugs often have a very narrow therapeutic index (TI), a more precise PK/PD model is required 302 
to estimate the FIH dose.  Novel PK/PD models tends to combine diverse properties including 303 
pharmacology ( potency, selectivity), preclinical safety profiles (doses and exposure related to 304 
toxicity), risk assessment (target and chemical assessment) and surrogate biomarkers such as 305 
those related to clinical and toxicity endpoints into the same framework to better predict the 306 
FIH dose [101-104]. One recent example added a pharmacogenomics dimension to the PK/PD 307 
model to define equivalent PK/PD dosing regimens for different genetically distinct tumor 308 
models [105]. Such a concept has been successfully used to define the FIH dose of epidermal 309 
growth factor receptor (EGFR) inhibitors such as gefitinib for different EGFR mutation carrier 310 
groups [106]. 311 
Preclinical models may perform well and effectively, but only when the context is well -defined 312 
and data are interpreted with care. To reproduce successful cases and apply valuable 313 
experience into anticancer drug preclinical practice, the comprehensive and critical re-314 
evaluation of cell-based and animal models is essential. Some of the large-scale consortium 315 
efforts and available public datasets make it possible to conduct meaningful retrospective 316 
analyses of quality control  suitability of the disease context and the utility of preclinical 317 
anticancer tools [107-109]. Furthermore, some alternative approaches such as the Phase 0 318 
clinical trial may be a promising complementary tool in pre-clinical anticancer models [110-319 
112]. A phase 0 clinical trial is conducted prior to the conventional clinical phase I dose 320 
escalation, tolerability assessment, and safety evaluation with limited human expose (usually 321 
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10-15 patients) and short period (typically with one week) and aims to optimize the PK/PD 322 
features especially oral bioavailability and half-life of anticancer drugs. 323 
 324 
Divergence between Clinical Phase II and Phase III 325 
According to statistics of Clinical Development Success Rates between 2006-2015 326 
(https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%20200327 
6-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf), anticancer drug 328 
development suffers a higher failure rate  (75.4%) from clinical Phase II to Phase III when 329 
compared to non-oncology drugs (65.7%). The FDA recently published a report entitled “22 330 
Case Studies Where Phase 2 and Phase 3 Trials Had Divergent Results” 331 
(http://www.fda.gov/aboutfda/reportsmanualsforms/reports/ucm535541.htm). Among the 22 332 
cases, five drugs (5/22=22.7%) are oncological agents (see Table 2). The major reason for 333 
anticancer drug failure from clinical Phase II to Phase III is lack of efficacy [113, 114]. 334 
Improvement of survival rate in patients is considered as the gold standard for anticancer drugs 335 
in clinical trial. Clinical endpoints such as overall survival (OS), disease-free survival (DFS), 336 
progress-free (PFS), time to progression (TTP) are also widely applied in cancer clinical studies.  337 
One of the difficult lessons from the past few decades of anticancer drug development is that 338 
positive results in Phase II do not guarantee a subsequent success in Phase III. This could be 339 
because the limited patient population in Phase II trials may not accurately reflect the broader 340 
patient population in Phase III trials. Furthermore, clinical endpoints in Phase II may be related 341 
to controlling signs of disease over the short-term such as PFS  which is easier to achieve than 342 
the desired clinical endpoint for success in Phase III, which is lengthening lifespan . Thus, these 343 
two endpoints may not correlate. In addition, the statistical measure in the smaller Phase II 344 
population may suffer from over-fitting, in which the benefits ascribed to the drug treatment 345 
are actually the result of random noise, and thus do not translate into larger populations. 346 
Specifically, the statistical model may outperform within the context of Phase II but not within 347 
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the extended patient population in the clinical Phase III.  Alternatively, there may be simple bias 348 
which is less likely to occur in the larger patient population in Phase III.  349 
Elimination of the divergence between Phase II (“therapeutic exploratory”) and Phase III 350 
(“therapeutic confirmatory”) is the key to improving successful rates for anticancer drug 351 
development.  Patient recruitment in the late-stage clinical trials has been a great stumbling 352 
block. Around 20% of cancer clinical trials were never finished due to insufficient patient 353 
enrollment, which is largely attributed to uncertain benefit to the cancer patients participating 354 
in the trials [115] n addition, more sensitive surrogate biomarkers are needed for use in the 355 
clinical trials. Patient recruitment in a clinical trial is mainly based on the pathology and 356 
morphology of diseases, which aims to collect homogeneous populations. However, patients 357 
collected in Phase III are substantially genetically heterogeneous [116]. For instance, the 358 
patients may carry different genetic mutations that are related to wholly different cancer 359 
subtypes, and therefore the compound under evaluation may have widely varied effects on 360 
these diverse tumors. With the advances in high-throughput “omics” techniques, it is possible 361 
to collect more information on patients such as genetic background and epigenetic properties 362 
to facilitate patient recruitment in Phase III.  363 
The divergence among the population does not just exist in different clinical trial phases but 364 
also manifests in the post-marketing stage. One example is bevacizumab (Avastin®). 365 
Bevacizumab  a vascular endothelial growth factor (VEGF) inhibitor, is the best-selling 366 
anticancer drug in the world, which was approved to treat multiple cancers such as colon 367 
cancer, lung cancer, and glioblastoma. In 2008, bevacizumab was approved by the FDA to treat 368 
metastatic breast cancer. However, this approval was revoked by FDA due to hypertension and 369 
kidney toxicity and poor progression-free survival profiles from post-marketing studies [117]. 370 
Another example is ponatinib, a BCR-ABL tyrosine kinase inhibitor (TKI). In clinical Phase II 371 
studies of ponatinib, there were a total of 449 patients involved. Among the 449 patients, only 372 
the 128 patients carrying the T351l mutations in BCR-ABL had a positive response to the 373 
treatment. However, ponatinib was given fast-track approval by the FDA on the basis of these 374 
Phase II results, and as such, was approved for chronic myeloid leukemia (CML) for the general 375 
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population in December 2012. Then, some published results the following year reported 376 
incidents of severe cardiovascular toxicity in patients taking ponatinib, causing the FDA to 377 
suspend approval of the drug. Just seven weeks later, the FDA provided guidance to 378 
reintroduce ponatinib back to the U.S. market for a more specific patient group (T351I mutation 379 
carriers) with CML [118]. These two examples highlight the divergence between the clinical 380 
study and general population groups and its consequence to the anticancer drug approval 381 
process, which also stimulates us to rethink the current clinical design of anticancer drug trials. 382 
First, the current clinical endpoints for anticancer drugs are focused on the time-to-event type, 383 
which creates a lot of problems when translated from one clinical phase to another due to both 384 
unclear biological meaning and statistical measures.   More effective biomarkers relevant to 385 
cancer pathology and drug pharmacology are urgently needed to improve the translation from 386 
one clinical trial to the next. Biomarkers that  more accurately reflect the efficacy and clinical 387 
benefits of anticancer treatment may improve performance of the compounds in clinical trials. 388 
Examples of possible biomarkers include circulating tumor DNA, concentration of antigen KI67 389 
in the serum level, and circulating tumor cell (CTC) counts [117]. Secondly, the clear endpoints 390 
and desired target population should be fully taken into consideration in the design of clinical 391 
trials and patient recruitments. Specifically, the genetic background of recruited patients could 392 
be helpful to identify patients with specific genetic mutations most likely to benefit from the 393 
study drug. With the decreased cost (less than $1,000) of sequencing techniques and advanced 394 
PCR assays, it is more possible to implement genetic testing as part of  clinical trials. 395 
Anticancer drug resistance  396 
One of the chief lessons that has emerged in the past two decades of anticancer drug 397 
development is that the promise of targeted therapy is tempered by the realities of drug 398 
resistance. Cancer drug resistance, in which the tumor cells are either inherently unresponsive 399 
to the treatment drug or develop changes that allow them to tolerate the drug, is one of the 400 
biggest challenges in anticancer drug development. Some known mechanisms that promote or 401 
induce anticancer drug resistance include drug transport and metabolism such as drug efflux 402 
and drug activation/inactivation, drug target alterations, DNA damage repair and downstream 403 
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resistance mechanisms such as deregulation of apoptosis and autophagy [119]. These 404 
mechanisms are divided into two categories: intrinsic and acquired. Intrinsic resistance means 405 
the resistant is pre-existing in the tumor cells before the chemotherapy. Acquired resistance 406 
occurs in the cancer development process, which can involve sub-cloning of tumor somatic 407 
mutations, increased target expression level and recruitment of alternative compensatory 408 
signaling pathways [120]. Moreover, molecular and genetic heterogeneity present in tumors 409 
contributes substantially to drug resistance [121].  410 
Although diverse underlying mechanisms of anticancer drug resistance have been deciphered in 411 
the past two decades, we still have a long road ahead before we have sufficient knowledge to 412 
overcome this issue.  [119]. Often tumors display multiple drug resistance (MDR), which is one 413 
of the major reasons for ineffectiveness and toxicity of chemotherapeutic agents [122]. The 414 
ATP-binding cassette (ABC) transporter family was identified as one of the causal factors for 415 
MDR. There are a total of 49 ABC transporters. However, very few proteins such as MDR1, 416 
MPR1, and BCRP have has been studied and identified in relation to MDR [123]. Initial efforts to 417 
develop ABC transporter inhibitors such as MDR1 inhibitors to overcome tumor resistance have 418 
yielded disappointing clinical outcomes. The first generation of MDR inhibitors had low affinity 419 
for ABC transporters, and increased dosing caused unexpected side effects [124]. The second 420 
and third generation MDR inhibitors had improved pharmacological profiles with higher affinity 421 
to ABC transporter. However, the clinical effectiveness is still suboptimal. For instance, the 422 
MDR1 inhibitor tariquidar was proposed as an adjuvant against multidrug resistance in late-423 
stage breast cancer. However, the clinical trial (phase II) showed no benefit for patients’ 424 
survival[125]. The possible reason may be the functional redundancy within the ABC 425 
transporter family or that other contributors, beyond ABC transporters, affect tumor resistance. 426 
Some preclinical cell-based HTS screening panels has been developed for ABC transporter 427 
screening, which could be important reference information in monitoring potential MDR [126]. 428 
Furthermore, rational drug combinations have been proposed to conquer MDR by targeting 429 
multiple components of the cancer process to improve the efficacy and overcome tumor 430 
resistance [127]. Research increasingly indicates that drug combinations that target multiple 431 
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pathways are more effective than targeting multiple targets within the same cancer-related 432 
pathway [119]. Tumors evolve over time in terms of their epigenetics, genetics and gene 433 
expression levels, which causes tumor initiation, metastasis, and drug resistance. Mutations 434 
that arise in the early stage tumors could further evolve into very different mutation types, 435 
which may cause the tumor to adapt and develop resistance to treatment. One example of 436 
evolving mutations is provided by gefitinib, which is an epidermal growth factor receptor 437 
(EGFR) inhibitor designed for non-small-cell lung cancer (NSCLC) treatment. Gefitinib is effective 438 
in patients with specific activating mutations in EGFR such as L858R in exon 21 but these 439 
benefits often last only for the first year of treatment. However, the evolving tumor acquires a 440 
new gatekeeper mutation named EGFR-T790M to maintain the genetic information and control  441 
the tumor growth, which cause 50% of patients to experience drug resistance and ultimately 442 
treatment failure [128]. In some cases, researchers have designed second-generation drugs that 443 
overcome the initial resistance. One example is the BCR-ABL1 oncogenic kinase inhibitors for 444 
chronic myeloid leukemia (CML). The first BCR-ABL1 inhibitor was effective but patients 445 
relapsed due to sub-cloning of the T315I mutation of BCR-ABL1. Drug makers developed the 446 
second generation of BCR-ABL1 inhibitors such as dasatinib and bosutinib against the T351I 447 
mutation in BCR-ABL1 [129].  448 
With the wide spectrum of cancer drug resistance mechanisms, it seems unlikely that the 449 
dream of a “magic bullet” to cure  cancer will ever be realized [119]. However, we should not 450 
lose sight of significant progress being made as anticancer drugs have become more precise 451 
and have prolonged and improved patients’ lives. With the assistance of modern omics 452 
techniques, we are experiencing a substantial increase in our ability to identify the molecular 453 
mechanisms for cancer drug resistance. Thus, the cumulative experience of cancer drug 454 
resistance research, from conventional chemotherapy to target-based therapies, can serve as 455 
the foundation to drive further research and to increase the number and effectiveness of 456 
anticancer drugs. 457 
New trends for anticancer drug development 458 
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As novel technology is increasingly applied to the challenge of cancer, new opportunities are 459 
emerging to innovate in anticancer drug development. Here is a glimpse at some of the great 460 
strides including precision medicine, cancer stem cells, and drug repositioning (more in Figure 461 
4). 462 
Precision medicine 463 
Precision medicine is an approach to integrate molecular and clinical information to better 464 
understand of disease by using novel genomics techniques such as next generation sequencing 465 
[18, 130]. Precision medicine aims to utilize the unique genetic profiles of patients to look for 466 
better treatment solution, which provides the right drug, the right dose to the right patients 467 
with reduced safety concern.  468 
Targeted cancer therapy as an important practice of precision medicine is considered as an 469 
indispensable components of current anticancer drugs development [131]. Unlike the 470 
conventional chemotherapy, targeted cancer therapy works on the specific target in cancer-471 
related molecular pathways to treat cancer. Targeted cancer agents are broadly divided into 472 
small molecules and monoclonal antibodies. The small molecule based targeted cancer agent is 473 
able to interact with the target inside the cell by penetrating the cell membrane, and 474 
monoclonal antibodies are designed to target specific antigen on the cell surface. For example, 475 
trastuzumab as a monoclonal antibody is designed to treat HER2 related breast cancer, which is 476 
only beneficial to the patients with HER2 protein overexpressed [132]. The precision medicine 477 
provides more deep resolution of genetic feature of cancer patients, which makes the patients 478 
with different genetic mutation as a group to receive the specific treatment option possible. 479 
The successful examples include imatinib for patients with chronic myeloid leukemia carrying a 480 
BCR-ABL mutation [133] and vemurafenib for those with melanoma or thyroid cancer who have 481 
the BRAF V600E variant [134]. The implementation of precision medicine requires the 482 
integration of molecular diagnosis into the anticancer drug discovery process [135]. Currently, 483 
there are approximately 35% (71/203) established pharmacogenomics biomarkers for approved 484 
anticancer drugs and incorporated into FDA-approved drug labeling .  485 
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The qualified biomarker or “fit-for-purpose” biomarker is the key to precision medicine practice 486 
[136]. Rich resources on genetic variants and their relationship in human cancers are available 487 
[137, 138]; however, understanding of how to leverage these findings into clinical practice 488 
(from the relationship, correlation to translation) is still suboptimal. Furthermore, there are 489 
some concerns over how many patients could actually benefit from precision medicine [139, 490 
140]. One disappointing report on personalized cancer treatment based on genetic biomarkers 491 
found only 30% patients had a positive response to personalized cancer treatment strategy and 492 
this amounted to an average two-month improvement of progression-free survival [141]. As 493 
highlighted recently, in ‘precision medicine’ the word ‘precision’ is being used in a colloquial 494 
sense, to mean both ‘accurate’ and ‘precise’. Precision implies a high degree of certainty of an 495 
outcome but in fact, the opposite will probably result. The new tools for tailoring treatment will 496 
demand a greater tolerance of uncertainty, a greater ability to interpret ‘omics’ data and a 497 
greater facility for calculating and interpreting probabilities than we have been used to as 498 
physicians and patients [142, 143]. Furthermore, although the price of next generation 499 
sequencing for diagnosis is continually decreased, the expanse for development personalized 500 
medicine based on individual genetic characteristics is still huge. Therefore, more efforts should 501 
be encouraged to standardize precision medicine practice in both clinical translation and the 502 
regulatory setting [144, 145].  503 
Cancer stem cells 504 
The discovery of cancer stem cells (CSCs) in the late 1990s triggered intense research efforts 505 
into this specialized subpopulation of tumor cells. CSCs, also referred to as tumor-initiating cells 506 
(TICs) can self-renew and drive tumorigenesis [146, 147]. CSCs play an important role in cancer 507 
initiation [148, 149], maintenance [150, 151], metastasis [152] and recurrence[153-155]. 508 
Therefore, a lot of efforts have been made to decipher CSC function in cancer pathogenesis, 509 
and to apply these findings in anticancer drug development [156].  510 
To date, CSCs have been discovered in multiple types of solid tumors such as breast cancer 511 
[157], lung cancer [158], and brain cancer [159]. Some targeting cellular surface markers 512 
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including CD133 [160], CD90 [161], CD33 [162] and PKA [163], key pathways such as Norch, 513 
Hedgehog, Wnt, and NF-κB signaling pathways [164], and transporters including ATP-binding 514 
cassette (ABC) transporters [165] have been detected in CSCs. Studies have sought ways to 515 
specifically target CSCs. Fang et. al. [166] performed HTS screening of small molecules and 516 
found LF3 (a 4-thioureido-benzenesulfonamide derivative) could effectively block the self-517 
renewal of cancer stem cells and suppresses tumorigenesis. The finding was also verified by 518 
using a mouse xenograft model of colon cancer. Masuda et. al. [167] found that small-molecule 519 
Traf2- and Nck-interacting kinase (TNIK) inhibitor, NCB-0846 could downregulate Wnt/β-catenin 520 
signaling by using Tnik−/−/Apcmin/+ mutant mice, which is essential to maintain the function of 521 
CSCs.  522 
Translation of  CSC research findings into anticancer drug development is still in the early stages 523 
[168]. The underlying mechanisms of how CSCs contribute to cancer progression are still not 524 
fully uncovered, and so efforts continue to unravel the biology [169-171]. However, CSCs 525 
remain a promising tool in anticancer drug development. Novel strategies such as 526 
nanomedicine targeting the CSC microenvironment are also being explored [172, 173].  527 
Drug repositioning  528 
Drug repositioning, an approach of finding new uses for existing drugs, has been attracting a lot 529 
of attention [22, 174]. By integrating different biological, chemical and genomics data profiles, 530 
drug repositioning can provide a rapid method to verify hypotheses and generate candidates 531 
for clinical validation. With the successful clinical application of non-cancer drugs for cancer 532 
treatment, drug repositioning becomes a powerful tool for anticancer development. 533 
Considering cancer often involves multiple pathologies [175], drug repositioning for 534 
combination therapy may be a promising direction [176]. 535 
Various drug repositioning approaches have been developed and could be potentially applied 536 
to anticancer drug development with initial evidence coming from preclinical models or 537 
controlled population studies (Table 3). The classic story is thalidomide, which was first 538 
marketed in 1957 in West Germany as a sedative and hypnotic. Afterward, it was also used 539 
 21 
 
against nausea or alleviating morning sickness in pregnant women. However, severe adverse 540 
reactions characterized by birth defects occurred and 60% of affected children died. Later, 541 
researchers found thalidomide could inhibit NF-ƙB and STAT3, and it was approved by the FDA 542 
for treating multiple myeloma in 2006 Another example is metformin. Metformin, as a first-line 543 
drug for type II diabetes, has been demonstrated to be an alternative therapy for multiple 544 
cancers with both chemopreventive and chemotherapeutic functions by single or combination 545 
therapy with other drugs [177-179]. The cancer prevention and anticancer activity of metformin 546 
have been demonstrated in cell-based assays[180, 181], animal models [181, 182] and 547 
controlled population studies [183]. Furthermore, aspirin as a nonsteroidal anti-inflammatory 548 
drug (NSAID) has been reported to reduce cancer risk with regular intake. Currently, the world-549 
largest clinical Phase III trial is underway in the UK to evaluate aspirin for its potential 550 
effectiveness to treat cancers such as  breast, colorectal, and prostate [184]. 551 
The increasing interest in drug repositioning for anticancer treatment development is mainly 552 
driven by the desire to use discontinued drugs and further exploit existing drugs with known 553 
PK/PD properties and safety profiles [176]. Some promising directions for anticancer 554 
repositioning include treating cancer by targeting the microenvironment, triggering immune 555 
systems by approved drugs [185]. Brian et. al. [185] mapped 1309 drugs onto 221 immune cell 556 
types based on their transcriptomic signature and predicted ~70,000 interactions. In addition, 557 
the authors experimentally validated the influence of one candidate drug (clioquinol) on 558 
neutrophil migration from the bone marrow to the blood in 6- to 12-week-old female C57Bl/c 559 
mice to investigate how the drug perturbs the immune systems.  The proposed methodology 560 
may be useful for immune-related anticancer drug candidate profiling. However, attention 561 
should be paid to the complex pathological and etiological features of cancers, which are very 562 
different from other common diseases. For example, cancer patients are a vulnerable 563 
population and a drug that does not have safety issues in healthier patients might trigger 564 
problems for them, especially if used in novel combinations [186]. Furthermore, the rationale 565 
behind non-cancer drugs treating cancer is that off-target effects driven by the 566 
polypharmacology of non-cancer drugs could be beneficial to the cancer patents’ survival. Since 567 
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the known PK/PD properties of non-cancer drugs are derived from data in the original 568 
indication, it is not guaranteed that the PK/PD features are still the same. Accordingly, the 569 
safety profiles should be also evaluated.  570 
Concluding Remarks 571 
By revisiting the anticancer drug development in the past two decades, we observe that a lot of 572 
encouraging progress has been made to improve cancer patients’ survival and quality of life. 573 
Meanwhile, there are still a lot of hurdles and unsolved difficulties in anticancer drug 574 
development (see the Outstanding Questions). Furthermore, anticancer drugs tend to 575 
command extremely high prices due to unmet and urgent needs of the market and patients 576 
[187]. We have highlighted here some successes from the past twenty years, along with the 577 
challenges posed by translational from preclinical to clinical trials, from a small population to 578 
the larger population, and limited qualified biomarkers in the anticancer drug paradigm. All 579 
three of these issues draw attention to the need to reevaluate our current anticancer drug 580 
development tools and redefine clinical context for their implementation. With the advantage 581 
of biology, genetic engineering, and emerging techniques, more and more novel concepts such 582 
as precision oncology and animal models such as PDXs have been successfully applied to drive 583 
innovation in the anticancer drug discovery pipeline. However, utilization to truly harness these 584 
advances to facilitate and accelerate anticancer development is still suboptimal. Some 585 
uncertainties still exist with novel techniques, providing a barrier to robust and reliable results. 586 
It is suggested that more perspective-retrospective studies should be conducted to build the 587 
standards and guidance for application of novel anticancer development tools with 588 
multidisciplinary efforts from regulatory agencies, drugmakers, and academic researchers. We 589 
are delighted that a lot of activities have been advocated and promoted such as Cancer 590 
Moonshot [188], Patient-Reported Outcomes (PROs) [189, 190], FDA Biomarker Qualification 591 
Program , and PrecisionFDA , which build the communication bridges among the patients, drug-592 
makers and regulatory agencies to move this field forward.  593 
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Anticancer drug development covers a wide spectrum of multidisciplinary fields. Some points 594 
not touched on and covered in depth here also hold promise in anticancer drug development. 595 
For example, genetic elements such as miRNAs also provide a new avenue for looking for 596 
cancer treatment options [191]. In addition, one of the gene therapies approach aims to add 597 
new genes to a patient's cells to replace missing or malfunctioning genes [192, 193], which may 598 
play an important role in future cancer treatment development with precise gene editing 599 
technologies such as CRISPR/Cas9 gene editing now available [194, 195]. Furthermore, cancer-600 
derived induced pluripotent stem cells (iPSCs) also provide a tremendous opportunity to model 601 
the effects of the cancer genome back to animal models for anticancer drug discovery [50, 196, 602 
197].  603 
Anticancer drug development has shifted from conventional cytotoxics agents to targeted-604 
based therapy and immunotherapy in the past two decades. Whether the new concepts and 605 
models truly fit within the established anticancer drug development paradigm is still an open 606 
question. A rethink of the existing anticancer drug discovery pipeline could refresh our minds to 607 
define pitfalls and further improve successful rates.  Furthermore, cancer drug development is a 608 
collaborative activity that requires drug makers, researchers, patients and regulatory agencies 609 
to form a cohesive strategy to accelerate and improve drug development to improve the life 610 
quality of cancer patients.  611 
Resources 612 
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 613 
Human Use (ICH) S9: https://www.fda.gov/downloads/Drugs/Guidances/ucm085389.pdf). 614 
NCI cancer-related clinical trials: https://www.cancer.gov/about-cancer/treatment/clinical-615 
trials/advanced-search 616 
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 617 
Human Use (ICH) M3: 618 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances619 
/UCM292340.pdf 620 
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Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for 621 
Therapeutics in Adult Healthy Volunteers: 622 
http://www.fda.gov/downloads/drugs/guidances/ucm078932.pdf 623 
Table of Pharmacogenomic Biomarkers in Drug Labeling: 624 
https://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.ht625 
m 626 
FDA Biomarker Qualification Program: 627 
https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificatio628 
nProgram/BiomarkerQualificationProgram/default.htm) 629 
PrecisionFDA: https://precision.fda.gov/ 630 
Seed and soil hypothesis:  631 
http://www.nature.com/milestones/milecancer/full/milecancer01.html 632 
NCI Cancer Statistics: https://www.cancer.gov/about-cancer/understanding/statistics 633 
NCI drug repository: https://www.cancer.gov/about-cancer/treatment/drugs 634 
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 1037 
Table 1 Examples of Divergency in anticancer drug candidates between Phase II-III* 1038 
Drug names Sponsor Therapeutic target Indication Notes 
Brivanib 
Bristol-Myers 
Squibb 
VEGFR and 
fibroblast growth 
factor receptors 
(FGFR) 
hepatocellular 
cancer 
Lack of efficiency. Brivanib failed to 
improve overall survival of patients 
compared to approved drug (i.e. 
sorafenib) and also demonstrated 
identified unexpected side effects. 
Iniparib Sanofi 
Poly(adenosine 
diphosphate–
ribose) polymerase 
1 (PARP1) 
Triple negative  
breast cancer 
Lack of efficiency. It was 
demonstrated that Inspired with 
standard chemotherapy regimen 
(gemcitabine and carboplatin) could 
not improve survival 
MAGE-A3 
vaccine 
GlaxoSmithKline 
Antigen for immune 
responses 
non-small cell 
lung cancer 
(NSCLC) 
Lack of efficiency. The clinical 
benefit could be proved when 
compared to a placebo 
Velimogene A 
liplasmid 
(Allovectin-7) 
Vical 
Antigen for 
cytotoxic T-cell and 
innate immune 
responses 
metastatic 
melanoma 
Lack of efficiency. Allovectin-7 
reduced tumor size significantly 
fewer patients than another two 
market drugs (i.e. dacarbazine and 
temozolomide) for late-stage 
melanoma patients. 
Figitumumab Pfizer 
insulin-like growth 
factor-1 receptor  
(IGF-1R) 
non-small cell 
lung cancer 
(NSCLC) 
Figitumumab with the standard 
regimen (paclitaxel and carboplatin) 
fails to improve the survival. 
Furthermore, severe adverse events 
(SAEs) such as pneumonia, 
dehydration and even death were 
observed  
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* The data is from “22 Case Studies Where Phase 2 and Phase 3 Trials Had Divergent Results” and curated from 1039 
https://www.fda.gov/aboutfda/reportsmanualsforms/reports/ucm535541.htm 1040 
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Table 2 Failed and on-going examples of animal models in anticancer drug development 
Animal model Tumor type Involved drug candidates Notes References 
Failed examples 
Cynomolgus and rhesus 
monkeys 
B-cell chronic lymphocytic 
leukemia (B-CLL) 
TGN1412 (agonistic anti-
CD28 antibody) 
Severe inflammatory 
reactions to immune system 
in Phase I 
[198, 199] 
Mouse medulloblastoma 
model 
Malignant solid brain tumor 
(medulloblastoma)/ 
Pancreatic Cancer 
Saridegib (Hedgehog 
pathway antagonist) 
Lack of efficiency when 
compared to placebo in 
clinical phase II  
[200, 201] 
Mouse-derived portion of the 
scFv on the CAR T cell 
Acute lymphoblastic 
leukemia (ALL) as well as 
relapsed or refractory (r/r) 
chronic lymphocytic 
leukemia and non-Hodgkin 
lymphoma (NHL) 
JCAR014 (a chimeric antigen 
receptor (CAR) T-cell 
receptor, targeting CD22) 
Patients Death due to in 
Phase I dose-escalation trial 
[202] 
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Table 3 Examples of drug repositioning for cancer therapy 
Drug  Original indication Suggested 
cancer 
mechanism 
Models  Notes References 
pioglitazone Type 2 diabetes  Multiple 
types 
 Pioglitazone could stabilize the elevated 
expression of the iron–sulfur (Fe-S) protein 
nutrient-deprivation autophagy factor-1 
(NAF-1), which is a key factor to cancer cell 
progression. 
[203] 
Flavopiridol Under clinical development 
of acute myeloid leukemia 
Glioblastoma Human 
glioblastoma 
cell lines 
Flavopiridol is a synthetic flavonoid that 
inhibits a wide range of Cyclin-dependent 
kinase, that has demonstrated to inactivate 
glycogen phosphorylase, decreasing glucose 
availability for glycolysis. It is suggested 
flavopiridol could combine with anti-
proliferative agents to treat glioblastoma. 
[204] 
rapamycin lymphangioleiomyomatosis pancreatic 
cancer 
Genetically 
engineered 
Targeted anti-mTOR therapies may offer 
clinical benefit in subsets of human 
[205] 
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mouse 
models 
pancreatic ductal adenocarcinoma (PDAC) 
selected based on genotype 
diflunisal Anti-inflammatory drug  leukemia leukemia cell 
lines and 
mouse model 
Diflunisal can suppress the growth of p300-
dependent leukemia cell lines expressing 
AML1-ETO fusion protein in vitro and in vivo 
[206] 
chloroquine antimalarial drug Multiple 
cancers 
normal cells 
in mice and 
cancer 
patients 
chloroquine (CQ), is a robust inducer of Par-
4 secretion from normal cells in mice and 
cancer patients in a clinical trial. CQ-
inducible Par-4 secretion triggers paracrine 
apoptosis of cancer cells and inhibits 
metastatic tumor growth. 
[207] 
JQ1 in 
combination 
with 
romidepsin 
romidepsin is used to 
cutaneous T-cell 
lymphoma (CTCL) and 
other peripheral T-cell 
lymphomas (PTCLs) 
Type II 
testicular 
germ cell 
cancers 
(TGCT) 
TGCT cell 
lines and 
Embryonal 
carcinoma 
(EC) 
xenografted 
mice models 
JQ1 in combination with romidepsin could 
reduce tumor size, proliferation rate, and 
angiogenesis 
[208] 
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metformin Type 2 diabetes  Multiple 
types 
Cancer cell 
line and 
mouse/rat 
models 
Metformin can inhibit mTORC1 pathway, 
which plays a pivotal role in metabolism, 
growth, and proliferation of cancer cell. 
[177, 178, 
180, 181, 
183] 
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Figure Captions  
Figure 1 Milestones in anticancer drug development in the past two decades 
Figure 2 The correlation between number of approved drugs and (A) percentage of 
survival in five years (2006~2012); (B) estimated newly added cases for each 
cancer type: the statistics for each cancer type were based on the Surveillance, 
Epidemiology, and End Results (SEER) Program of the National Cancer Institute 
(https://seer.cancer.gov/statfacts/) 
Figure 3 The key factors for translation of animal results to humans in anticancer drug 
development: species selection, applicability of animal models, toxicity profiles, 
and PK/PD model optimization. FIH dose = first-in-human dose; MTD = maximum 
tolerated dose 
Figure 4 New trends in anticancer drug development 
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